FDA Set To Review Teva’s Asthma Rescue Inhaler

July 15, 2014 | The US Food and Drug Administration (FDA) is set to review Teva Pharmaceutical Industries‘ drug application for the treatment of asthma, the albuterol multi-dose dry-powder inhaler (MDPI). According to a “Globes” report, the inhaler will be used to treat patients of 12 years of age or older for bronchospasm. Teva VP of Global Respiratory R&D Tushar Shah said, “If approved, albuterol MDPI would become the first breath-actuated dry-powder symptomatic and rescue inhaler available to asthma patients. As the current market-leader in asthma rescue inhalers, it is our hope that the new dry-powder innovation utilized with albuterol MDPI will help fill an unmet need in the existing asthma market.”